broadly neutralizing antibodies against enterovirus

Broadly neutralizing antibodies (bNAbs) against enterovirus represent an early-stage immunotherapy research program initiated by the Academisch Medisch Centrum (AMC) in the Netherlands. The program focuses on the generation and development of antibody-based therapeutics capable of neutralizing a wide spectrum of enterovirus strains, which are responsible for diverse clinical manifestations including hand, foot and mouth disease, viral meningitis, and encephalitis. By targeting conserved epitopes across the enterovirus genus, these bNAbs aim to provide a versatile treatment option for systemic and severe viral infections where specific antiviral therapies are currently limited.

Other names

enterovirus immunotherapy program